FOR IMMEDIATE RELEASE: 2019/10/4
M3, Inc,
Shionogi & Co., Ltd.

M3 and Shionogi Joint Venture for Disease Solution
- Establishment of Stream-I, Inc. -

M3, Inc. (Headquarters: Tokyo, Japan; CEO: Itaru Tanimura; “M3” below) and Shionogi & Co., Ltd. (Head office: Osaka, Japan; President & CEO: Isao Teshirogi, Ph.D.; “Shionogi,” below) announced today that both companies established a new joint venture “Stream-I, Inc.”. Stream-I, Inc. (Head office: Osaka, Japan; CEO: Takuko Sawada; “Stream-I” below) will integrate maximally assets and strengths of both companies with the objective to create disease solutions that are not limited to medication.

M3 operates m3.com, a specialized web portal for medical professionals that delivers healthcare related information to its 280,000+ physician members in Japan, and offers marketing and clinical trial services. Recent business expansion have been in areas such as AI diagnostic tool development, genome diagnostics provision, and stroke rehabilitation centers, no longer limited to pharmaceutical marketing. “7P Projects” aim to integrate such businesses in order to provide holistic solutions for multiple issues within individual therapeutic areas. Furthermore, presence outside of Japan include the U.S., U.K., France, China, Korea and India, with aggressive business expansion overseas that has amassed over 5.5 million physicians as members across our global platforms, allowing provision of a wide range of services.

Shionogi holds “Grow sustainably as a drug discovery-based pharmaceutical company contributing to a more vigorous society through improved healthcare” as a vision in the mid-term business plan SGS2020 which includes goals for addressing social missions such as “protecting people from the threat of infectious diseases” and “creating a more vigorous society.” In addition to contributing to the health and quality of life of patients around the world through providing innovative drugs discovered in focus therapeutic areas such as infectious diseases and pain/CNS disorder, Shionogi aims to support the well-being and quality of life for individuals through continued delivery of proper pharmaceutical information towards medical professionals via representatives such as MRs.
Stream-I aims to create a new information delivery model which integrates digital technology with existing physical resources to achieve the goal to “reduce as many patients who suffer from disease” by combining the strengths of both companies. Stream-I will strive to contribute to society through promoting progress in individual wellness and medical care productivity by addressing not only proper administration of treatment, but the entire patient journey starting from prevention to diagnosis, to treatment, and aftercare.

**JV Overview:**

Name: Stream-I, Inc.
CEO: Takuko Sawada
Established: October 2019
Capital: 50 million yen
Capital Structure: Shionogi & Co., Ltd. 51%, M3, Inc. 49%
Address: 3-1-8 Doshoumachi, Chuo-ku, Osaka
Employees: 13 (as of October 2019)

**Contact Details:**

<table>
<thead>
<tr>
<th>M3, Inc. PR</th>
<th>Shionogi &amp; Co., Ltd. Corporate Communications</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEL: 03-6229-8905</td>
<td>TEL: 06-6209-7885</td>
</tr>
</tbody>
</table>